Navigation Links
Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
Date:9/3/2009

BASKING RIDGE, N.J., Sept. 3 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that David J. Mazzo, Ph.D., President and Chief Executive Officer, will be presenting at the 11th Annual Healthcare Conference of the Rodman & Renshaw Global Investment Conference in New York, NY at 4:30 PM on Thursday, September 10, 2009 (EDT). Dr. Mazzo's presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006.

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.


'/>"/>
SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences REG1 Anticoagulation System Study Results Published in the Journal of Thrombosis and Haemostasis
2. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
3. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
4. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
5. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Regado Biosciences Establishes Medical Advisory Board
8. Regado Biosciences Expands Medical Advisory Board
9. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... Dr. Bob ... at his local San Diego Rotary Club. The event entitled “Stem ... CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
(Date:10/9/2017)... ... 2017 , ... The award-winning American Farmer television series will feature 3 Bar ... Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ten billion ... continue to feed a growing nation. At the same time, many of our valuable ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):